e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Interstitial lung diseases II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF
Lutz Wollin (Biberach Riss, Germany), Jennifer Schuett, Angela Ostermann, Lutz Wollin
Source:
International Congress 2015 – Interstitial lung diseases II
Session:
Interstitial lung diseases II
Session type:
Thematic Poster Session
Number:
3846
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Lutz Wollin (Biberach Riss, Germany), Jennifer Schuett, Angela Ostermann, Lutz Wollin. The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF. Eur Respir J 2015; 46: Suppl. 59, 3846
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Effect of pirfenidone on IPF progression
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors
Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Year: 2014
Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis
Source: International Congress 2015 – Airway remodelling: recent developments
Year: 2015
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone
Source: International Congress 2014 – ILDs 1
Year: 2014
LATE-BREAKING ABSTRACT: Anti-fibrotic effects of nintedanib and pirfenidone in 2D versus 3D lung cultures
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Source: International Congress 2015 – Treatment of IPF
Year: 2015
The efficacy of pirfenidone in scleroderma related interstitial lung disease
Source: Annual Congress 2012 - Diffuse parenchymal lung disease III
Year: 2012
Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016
Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2014 – ILDs 1
Year: 2014
Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept